The tumor-reactive T-cell signature identified by Lowery et al. [39] (Supplementary Table 5) was enriched in the CD8+_CXCL13 population (Supplementary Fig. 13G) and was significantly increased in patients in the IR+ group (Supplementary Fig. 13H). Here, CD8A is linked to neoplasm.